Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2025, titled "Cosmo and Glenmark Announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe ".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals, in partnership with Cosmo Pharmaceuticals, has received market authorization for Winlevi® (clascoterone) 10 mg/g cream for the treatment of acne in 15 European countries. This regulatory approval expands the commercial footprint of Winlevi® beyond its existing markets. The product is a topical treatment for acne, a common dermatological condition with large patient demand across Europe. The partnership with Cosmo leverages Glenmark's established dermatology distribution network in these regions. This marks an important commercial milestone for Glenmark's specialty/dermatology portfolio.
Positive for Glenmark as it opens up revenue opportunities across 15 European markets through an established dermatology product, potentially adding to specialty business growth in the coming quarters.